Williams-Sonoma, Inc. (WSM) Stock Price Today
Aura AI Summary
Key Stats
- $27.45BMARKET_CAP
- -VOLUME
- Consumer CyclicalSECTOR
- $240.06FIFTY_TWO_WEEK_HIGH
- $163.62FIFTY_TWO_WEEK_LOW
- -TYPICAL_HOLD_TIME
- $28.29BENTERPRISE_VALUE
- 1.34%DIVIDEND_YIELD
- -TRADING_ACTIVITY
Track Williams-Sonoma, Inc. (WSM) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Williams-Sonoma, Inc. has traded between a low of $163.62 and a high of $240.06, highlighting its annual price range. Buy and sell Williams-Sonoma, Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Most Recent News
Global Family Office Summit in Lake Como spotlights AI, private markets, and global investment trends.
The 32nd Global Family Office Investment Summit in Lake Como gathered over 200 family office leaders, investors, and entrepreneurs from 27 countries to discuss emerging trends in AI, private equity, healthcare innovation, and global investment opport...

GuideAI appoints vascular expert Dr. Benenati after FDA clears its AI vascular triage software VAOT
GuideAI Health Corp. has appointed Dr. James F. Benenati, a leading interventional radiologist, to its Advisory Board following FDA 510(k) clearance of its AI software, VascularAssist Occlusion Triage (VAOT). VAOT is designed to help radiologists pri...

VERAXA Biotech advances cancer therapy pipeline focusing on BiTAC technology and seeks partnerships.
VERAXA Biotech updated on its progress in developing novel cancer therapies using its proprietary BiTAC platform, focusing on conditionally active T cell engagers and bispecific antibody-drug conjugates. The company plans to prioritize investment in ...
